{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T10:08:37Z","timestamp":1789034917184,"version":"build-2803163510"},"reference-count":221,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immune checkpoint (IC) pathways, originally identified in T-cell exhaustion in cancer, are increasingly recognized as key modulators of immune tolerance in autoimmune diseases (ADs). In ADs, these molecules function more accurately as inhibitory receptors (IRs) that fine-tune, rather than inducing classical exhaustion phenotypes, autoreactive immune cells. Unlike oncology, where checkpoint blockade enhances immunity, AD therapy aims to restore tolerance through IC agonism or immune reset approaches (e.g., CAR-T cells). This review synthesizes recent advances in targeting CTLA-4, PD-1, LAG-3, TIM-3, and TIGIT. Clinical success with CTLA-4-Ig (abatacept) and emerging efficacy of PD-1 agonists (e.g., peresolimab) provide proof-of-concept that augmenting inhibitory signaling can ameliorate autoimmunity. However, outcomes remain context-dependent, reflecting interplay between effector and regulatory subsets and tissue-specific environments. Mechanistic challenges, including multivalent receptor engagement, ligand complexity, and signaling heterogeneity (e.g., ITIM\/ITSM phosphorylation), limit current approaches. Insights from immune-related adverse events (irAEs) highlight shared pathways of dysregulation and inform risk-benefit considerations. A major translational gap persists between acute transplant models and chronic autoimmunity, and validated predictive biomarkers are lacking. Beyond T cells, B cells, dendritic cells, and innate populations expand therapeutic opportunities. Future progress will require multi-omics profiling, biomarker-driven stratification, and next-generation agonist design. IC-targeted strategies hold promises but demand context-aware, mechanistically informed development for broad clinical impact in ADs.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1725372","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:17:56Z","timestamp":1789031876000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Harnessing tumor immune checkpoints for autoimmune disease therapeutics"],"prefix":"10.3389","volume":"17","author":[{"given":"Hanmei","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital and West China School of Basic Medical Sciences and Forensic Medicine, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Chengdu Integrated TCM & Western Medicine Hospital","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital and West China School of Basic Medical Sciences and Forensic Medicine, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital and West China School of Basic Medical Sciences and Forensic Medicine, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guobo","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital and West China School of Basic Medical Sciences and Forensic Medicine, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(22)01349-6","article-title":"Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK","volume":"400","author":"Conrad","year":"2022","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103359","article-title":"Temporal trends in the prevalence of autoimmune diseases from 1990 to 2019","volume":"22","author":"Cao","year":"2023","journal-title":"Autoimmun Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)00457-9","article-title":"Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK","volume":"401","author":"Conrad","year":"2023","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdin.2024.11.003","article-title":"Global trends in immune mediated inflammatory diseases: Psoriasis, atopic dermatitis, multiple sclerosis, inflammatory bowel disease, and rheumatoid arthritis","volume":"18","author":"Gelabert-Mora","year":"2025","journal-title":"JAAD Int"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102743","article-title":"An updated advance of autoantibodies in autoimmune diseases","volume":"20","author":"Xiao","year":"2021","journal-title":"Autoimmun Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2019.09.004","article-title":"B cell targeted therapies in autoimmune disease","volume":"61","author":"Barnas","year":"2019","journal-title":"Curr Opin Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)31472-1","article-title":"Pathogenetic insights from the treatment of rheumatoid arthritis","volume":"389","author":"McInnes","year":"2017","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.03.014","article-title":"Regulation and function of the PD-L1 checkpoint","volume":"48","author":"Sun","year":"2018","journal-title":"Immunity"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.97002","article-title":"Immune checkpoint dysregulation in autoimmune disorders: A narrative review of therapeutic implications","volume":"17","author":"Khan","year":"2025","journal-title":"Cureus"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy-current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/mog2.70030","article-title":"Targeting immune checkpoints: Basic signaling pathways and clinical translation in cancer therapeutics","volume":"4","author":"Sun","year":"2025","journal-title":"MedComm \u2013 Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1172\/JCI96107","article-title":"PD-1+CD8+ T cells are clonally expanding effectors in human chronic inflammation","volume":"128","author":"Petrelli","year":"2018","journal-title":"J Clin Invest"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1172\/JCI120859","article-title":"Kidney-infiltrating T cells in murine lupus nephritis are metabolically and functionally exhausted","volume":"128","author":"Tilstra","year":"2018","journal-title":"J Clin Invest"},{"key":"B14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/nature14468","article-title":"T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection","volume":"523","author":"McKinney","year":"2015","journal-title":"Nature"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2018.01.026","article-title":"Immune checkpoint failures in inflammatory myopathies: An overview","volume":"17","author":"Herbelet","year":"2018","journal-title":"Autoimmun Rev"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: Clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu Rev Pathol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"108647","DOI":"10.1016\/j.intimp.2022.108647","article-title":"An overview of immune checkpoint therapy in autoimmune diseases","volume":"107","author":"Mohammadi","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"16039","DOI":"10.1038\/nrdp.2016.39","article-title":"Systemic lupus erythematosus","volume":"2","author":"Kaul","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1155\/jimr\/5006201","article-title":"Immune tolerance regulation is critical to immune homeostasis","volume":"2025","author":"Han","year":"2025","journal-title":"J Immunol Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1730575","article-title":"Global trends of peripheral immune tolerance research: a bibliometric and visualization analysis","volume":"17","author":"Kong","year":"2026","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.19","article-title":"Mechanisms of central tolerance for B cells","volume":"17","author":"Nemazee","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41577-024-01076-8","article-title":"Antigen presentation for central tolerance induction","volume":"25","author":"Klein","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2024.01.010","article-title":"LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation","volume":"57","author":"Joller","year":"2024","journal-title":"Immunity"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2025.07.001","article-title":"Cell-intrinsic CD4 T cell tolerance: a new frontier in therapy","volume":"46","author":"Cassano","year":"2025","journal-title":"Trends Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000001117","article-title":"CTLA4-related primary immune dysregulatory disorders","volume":"25","author":"Cassano","year":"2025","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.70962\/jhi.20250112","article-title":"Immune dysregulation from a novel CTLA-4 haploinsufficiency variant","volume":"2","author":"Brodsky","year":"2026","journal-title":"J Hum Immun"},{"key":"B29","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/s0065-2776(08)60633-1","article-title":"Self-tolerance checkpoints in B lymphocyte development","volume":"59","author":"Goodnow","year":"1995","journal-title":"Adv Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12395","article-title":"Human autoimmune diseases: a comprehensive update","volume":"278","author":"Wang","year":"2015","journal-title":"J Intern Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.10.5340","article-title":"Inducing autoimmune disease to treat cancer","volume":"96","author":"Pardoll","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"B32","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/s0065-2776(06)90008-x","article-title":"Checkpoint blockade in cancer immunotherapy","volume":"90","author":"Korman","year":"2006","journal-title":"Adv Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41392-023-01365-z","article-title":"Emerging phagocytosis checkpoints in cancer immunotherapy","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2025.01.240","article-title":"The moonlighting function of glutamin synthase 2 promotes immune evasion of pancreatic ductal adenocarcinoma by tubulin tyrosine ligase-like 1-mediated Yes1 associated transcriptional regulator glutamylation","volume":"168","author":"Chen","year":"2025","journal-title":"Gastroenterology"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition","volume":"13","author":"Chen","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.immuni.2021.12.012","article-title":"Metabolic adaptation of lymphocytes in immunity and disease","volume":"55","author":"Chapman","year":"2022","journal-title":"Immunity"},{"key":"B37","doi-asserted-by":"publisher","first-page":"6692","DOI":"10.1038\/ncomms7692","article-title":"PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation","volume":"6","author":"Patsoukis","year":"2015","journal-title":"Nat Commun"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e220007","DOI":"10.20900\/immunometab20220007","article-title":"Effects of PD-1 signaling on immunometabolic reprogramming","volume":"4","author":"Boussiotis","year":"2022","journal-title":"Immunometabolism"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/nri1632","article-title":"NFAT proteins: key regulators of T-cell development and function","volume":"5","author":"Macian","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2307020","article-title":"Phase 2 trial of peresolimab for adults with rheumatoid arthritis. Reply","volume":"389","author":"Tuttle","year":"2023","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1566869","article-title":"Immune inhibitory receptor agonist therapeutics","volume":"16","author":"Lovewell","year":"2025","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05673-2","article-title":"Reducing affinity as a strategy to boost immunomodulatory antibody agonism","volume":"614","author":"Yu","year":"2023","journal-title":"Nature"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.04.022","article-title":"Costimulatory and coinhibitory receptor pathways in infectious disease","volume":"44","author":"Attanasio","year":"2016","journal-title":"Immunity"},{"key":"B44","doi-asserted-by":"publisher","first-page":"eaaw7888","DOI":"10.1126\/scitranslmed.aaw7888","article-title":"A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies","volume":"12","author":"Skokos","year":"2020","journal-title":"Sci Transl Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.04.020","article-title":"CD28 costimulation: From mechanism to therapy","volume":"44","author":"Esensten","year":"2016","journal-title":"Immunity"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2024.01.013","article-title":"The B7:CD28 family and friends: Unraveling coinhibitory interactions","volume":"57","author":"Burke","year":"2024","journal-title":"Immunity"},{"key":"B47","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2009.04.023","article-title":"Association of CTLA4 but not ICOS polymorphisms with type 1 diabetes in two populations with different disease rates","volume":"70","author":"Douroudis","year":"2009","journal-title":"Hum Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/s0165-5728(02)00275-8","article-title":"CTLA4 exon 1 dimorphism is associated with primary progressive multiple sclerosis","volume":"131","author":"M\u00e4urer","year":"2002","journal-title":"J Neuroimmunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ejhg.5201214","article-title":"Evidence for CTLA4 as a susceptibility gene for systemic lupus erythematosus","volume":"12","author":"Barreto","year":"2004","journal-title":"Eur J Hum Genet"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/art.20040","article-title":"Association of a programmed death 1 gene polymorphism with the development of rheumatoid arthritis, but not systemic lupus erythematosus","volume":"50","author":"Lin","year":"2004","journal-title":"Arthritis Rheum"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20514","article-title":"A PD-1 polymorphism is associated with disease progression in multiple sclerosis","volume":"58","author":"Kroner","year":"2005","journal-title":"Ann Neurol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1608873113","article-title":"Nonoverlapping roles of PD-1 and FoxP3 in maintaining immune tolerance in a novel autoimmune pancreatitis mouse model","volume":"113","author":"Zhang","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-0769-3","article-title":"The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies","volume":"21","author":"Kumagai","year":"2020","journal-title":"Nat Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1198365","article-title":"Current understanding of CTLA-4: from mechanism to autoimmune diseases","volume":"14","author":"Hossen","year":"2023","journal-title":"Front Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1812186116","article-title":"Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody","volume":"116","author":"Ha","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-025-01562-6","article-title":"The role of coinhibitory receptor-expressing non-T cells in inflammation and immunity: unsung heroes or peripheral players","volume":"57","author":"Khaled","year":"2025","journal-title":"Exp Mol Med"},{"key":"B58","doi-asserted-by":"publisher","first-page":"4332","DOI":"10.3390\/ijms26094332","article-title":"Knockdown of TIM3 hampers dendritic cell maturation and induces immune suppression by modulating T-cell responses","volume":"26","author":"Chen","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2024.113757","article-title":"Comparative analysis of LAG3 antibodies shows differential binding patterns by flow cytometry","volume":"534","author":"Graydon","year":"2024","journal-title":"J Immunol Methods"},{"key":"B60","doi-asserted-by":"publisher","first-page":"5967","DOI":"10.3390\/cancers13235967","article-title":"Immune checkpoints and innate lymphoid cells-new avenues for cancer immunotherapy","volume":"13","author":"Jacquelot","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B61","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","article-title":"CTLA-4: a moving target in immunotherapy","volume":"131","author":"Rowshanravan","year":"2018","journal-title":"Blood"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-017-8603-x","article-title":"Memory B cells and response to abatacept in rheumatoid arthritis","volume":"53","author":"Gazeau","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103386","article-title":"Functional autoantibodies: definition, mechanisms, origin and contributions to autoimmune and non-autoimmune disorders","volume":"22","author":"Yu","year":"2023","journal-title":"Autoimmun Rev"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semcancer.2019.06.001","article-title":"Antibody therapeutics and immunoregulation in cancer and autoimmune disease","volume":"64","author":"Yasunaga","year":"2020","journal-title":"Semin Cancer Biol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.102333","article-title":"Immune checkpoint molecules. Possible future therapeutic implications in autoimmune diseases","volume":"104","author":"Huang","year":"2019","journal-title":"J Autoimmun"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.645699","article-title":"Immune checkpoints, a novel class of therapeutic targets for autoimmune diseases","volume":"12","author":"Zhai","year":"2021","journal-title":"Front Immunol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.694055","article-title":"Detection of immune checkpoint receptors - a current challenge in clinical flow cytometry","volume":"12","author":"Shibru","year":"2021","journal-title":"Front Immunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106221","article-title":"CTLA-4: from mechanism to autoimmune therapy","volume":"80","author":"Hosseini","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"106221","DOI":"10.1016\/j.intimp.2020.106221","article-title":"CTLA-4: from mechanism to autoimmune therapy","volume":"80","author":"Hosseini","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.4238\/2013.December.6.1","article-title":"Association between the Rs3087243 polymorphism and risk for diabetes: a meta-analysis","volume":"12","author":"Liu","year":"2013","journal-title":"Genet Mol Res"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1126\/science.1202947","article-title":"Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4","volume":"332","author":"Qureshi","year":"2011","journal-title":"Science"},{"key":"B72","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.it.2014.12.001","article-title":"Confusing signals: recent progress in CTLA-4 biology","volume":"36","author":"Walker","year":"2015","journal-title":"Trends Immunol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"306","DOI":"10.3390\/genes16030306","article-title":"CTLA4 alteration and neurologic manifestations: a new family with large phenotypic variability and literature review","volume":"16","author":"Genio","year":"2025","journal-title":"Genes (Basel)"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200351","article-title":"Abatacept induces long-term reconstitution of the B-cell niche in a patient with CTLA-4 haploinsufficiency: a case report","volume":"12","author":"Pfeuffer","year":"2025","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B75","doi-asserted-by":"publisher","first-page":"9230","DOI":"10.3390\/ijms26189230","article-title":"Neuroinflammation in CTLA-4 haploinsufficiency: case report of a new variant with remarkable response to targeted therapy","volume":"26","author":"Baldini","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2006.03.001","article-title":"CTLA4Ig: bridging the basic immunology with clinical application","volume":"24","author":"Bluestone","year":"2006","journal-title":"Immunity"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-020-0081-9","article-title":"Targeting co-stimulatory molecules in autoimmune disease","volume":"19","author":"Edner","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0775-4","article-title":"Abatacept: a review in rheumatoid arthritis","volume":"77","author":"Blair","year":"2017","journal-title":"Drugs"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1002\/art.40466","article-title":"Subcutaneous abatacept in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study","volume":"70","author":"Brunner","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12969-019-0319-4","article-title":"Intravenous abatacept in Japanese patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study","volume":"17","author":"Hara","year":"2019","journal-title":"Pediatr Rheumatol Online J"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1002\/art.39234","article-title":"Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years","volume":"67","author":"Lovell","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-2200","article-title":"Abatacept for delay of type 1 diabetes progression in stage 1 relatives at risk: a randomized, double-masked, controlled trial","volume":"46","author":"Russell","year":"2023","journal-title":"Diabetes Care"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(11)60886-6","article-title":"Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial","volume":"378","author":"Orban","year":"2011","journal-title":"Lancet"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-0604","article-title":"Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment","volume":"37","author":"Orban","year":"2014","journal-title":"Diabetes Care"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1080\/1744666x.2018.1485489","article-title":"Belatacept\/CTLA4Ig: an update and critical appraisal of preclinical and clinical results","volume":"14","author":"Schwarz","year":"2018","journal-title":"Expert Rev Clin Immu"},{"key":"B86","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1053\/j.gastro.2012.04.010","article-title":"Abatacept for Crohn's disease and ulcerative colitis","volume":"143","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2016.1154943","article-title":"Abatacept for the treatment of systemic lupus erythematosus","volume":"25","author":"Pimentel-Quiroz","year":"2016","journal-title":"Expert Opin Investig Drugs"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1177\/0961203320981146","article-title":"Drug-induced subacute cutaneous lupus erythematosus associated with abatacept","volume":"30","author":"Figueredo Zamora","year":"2021","journal-title":"Lupus"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-023-00867-9","article-title":"Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1","volume":"23","author":"Chamoto","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2021.101480","article-title":"Emerging concepts in PD-1 checkpoint biology","volume":"52","author":"Pauken","year":"2021","journal-title":"Semin Immunol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.7150\/thno.107418","article-title":"PD-1 activation mitigates lupus nephritis by suppressing hyperactive and heterogeneous PD-1(+)CD8(+) T cells","volume":"15","author":"Deng","year":"2025","journal-title":"Theranostics"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0505497102","article-title":"Establishment of NOD-Pdcd1-\/- mice as an efficient animal model of type I diabetes","volume":"102","author":"Wang","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2349","article-title":"Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy","volume":"38","author":"Hughes","year":"2015","journal-title":"Diabetes Care"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2762","article-title":"A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application","volume":"14","author":"Okazaki","year":"2013","journal-title":"Nat Immunol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1315828110","article-title":"Programmed cell death 1 inhibits inflammatory helper T-cell development through controlling the innate immune response","volume":"110","author":"Rui","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.36740\/WLek\/197185","article-title":"Association of program cell death ligand-1 (rs4143815 G>C) with some clinical symptoms and oral ulcer types in systemic lupus erythematosus","volume":"78","author":"Al-Terehi","year":"2025","journal-title":"Wiad Lek"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-015-0132-2","article-title":"Analysis of programmed death-1 in patients with psoriatic arthritis","volume":"38","author":"Peled","year":"2015","journal-title":"Inflammation"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-013-9718-8","article-title":"Expression of programmed death-1 (PD-1) on CD4+ and CD8+ T cells in rheumatoid arthritis","volume":"37","author":"Li","year":"2014","journal-title":"Inflammation"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1159\/000480641","article-title":"The systemic activation of programmed death 1-PD-L1 axis protects systemic lupus erythematosus model from nephritis","volume":"46","author":"Liao","year":"2017","journal-title":"Am J Nephrol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.03.004","article-title":"Negative co-stimulation constrains T cell differentiation by imposing boundaries on possible cell states","volume":"50","author":"Wei","year":"2019","journal-title":"Immunity"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1387975","article-title":"Regulation of Treg cells by cytokine signaling and co-stimulatory molecules","volume":"15","author":"Zong","year":"2024","journal-title":"Front Immunol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209856","article-title":"A phase 2 trial of peresolimab for adults with rheumatoid arthritis","volume":"388","author":"Tuttle","year":"2023","journal-title":"N Engl J Med"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201907692","article-title":"Engineered PD-L1-expressing platelets reverse new-onset type 1 diabetes","volume":"32","author":"Zhang","year":"2020","journal-title":"Adv Mater"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.03157","article-title":"PDL1 fusion protein protects against experimental cerebral malaria via repressing over-reactive CD8(+) T cell responses","volume":"9","author":"Wang","year":"2018","journal-title":"Front Immunol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-307311","article-title":"Protective effects of Fc-fused PD-L1 on two different animal models of colitis","volume":"64","author":"Song","year":"2015","journal-title":"Gut"},{"key":"B107","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clim.2015.10.006","article-title":"Treatment of murine lupus with PD-LIg","volume":"162","author":"Zhou","year":"2016","journal-title":"Clin Immunol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.11.021","article-title":"Programmed cell death ligand 1 alleviates psoriatic inflammation by suppressing IL-17A production from programmed cell death 1-high T cells","volume":"137","author":"Kim","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/s41551-019-0360-0","article-title":"Depletion of PD-1-positive cells ameliorates autoimmune disease","volume":"3","author":"Zhao","year":"2019","journal-title":"Nat BioMed Eng"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1002\/pro.4741","article-title":"Diphtheria toxin-derived, anti-PD-1 immunotoxin, a potent and practical tool to selectively deplete PD-1(+) cells","volume":"32","author":"Zhang","year":"2023","journal-title":"Protein Sci"},{"key":"B111","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"B113","doi-asserted-by":"publisher","first-page":"663","DOI":"10.3390\/cancers13040663","article-title":"Recent advancements in the mechanisms underlying resistance to PD-1\/PD-L1 blockade immunotherapy","volume":"13","author":"Yuan","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107933","article-title":"TIM-3: an update on immunotherapy","volume":"99","author":"Zhao","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.Cir-14-0039","article-title":"Tim-3: an emerging target in the cancer immunotherapy landscape","volume":"2","author":"Anderson","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.40","article-title":"Immunotherapy: PD-1 says goodbye, TIM-3 says hello","volume":"13","author":"Romero","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-310425","article-title":"Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia","volume":"117","author":"Zhou","year":"2011","journal-title":"Blood"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.770402","article-title":"Tim-3 relieves experimental autoimmune encephalomyelitis by suppressing MHC-II","volume":"12","author":"Tang","year":"2021","journal-title":"Front Immunol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1038\/415536a","article-title":"Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease","volume":"415","author":"Monney","year":"2002","journal-title":"Nature"},{"key":"B121","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s10238-021-00726-8","article-title":"Increased TIM-3(+)PD-1(+) NK cells are associated with the disease activity and severity of systemic lupus erythematosus","volume":"22","author":"Luo","year":"2022","journal-title":"Clin Exp Med"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1172\/jci97333","article-title":"Galectin-9 inhibits TLR7-mediated autoimmunity in murine lupus models","volume":"128","author":"Panda","year":"2018","journal-title":"J Clin Invest"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0060807","article-title":"Galectin-9 ameliorates clinical severity of MRL\/lpr lupus-prone mice by inducing plasma cell apoptosis independently of Tim-3","volume":"8","author":"Moritoki","year":"2013","journal-title":"PloS One"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00449","article-title":"Tim-3: an activation marker and activation limiter of innate immune cells","volume":"4","author":"Han","year":"2013","journal-title":"Front Immunol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1285","article-title":"Impaired expression of Tim-3 on Th17 and Th1 cells in psoriasis","volume":"92","author":"Kanai","year":"2012","journal-title":"Acta Derm Venereol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2025.106826","article-title":"Therapeutic potential of TIM-3 inhibition in cancer, viral infections, and autoimmune disorders","volume":"186","author":"Manzoor","year":"2025","journal-title":"Int J Biochem Cell Biol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2376","article-title":"Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1","volume":"13","author":"Chiba","year":"2012","journal-title":"Nat Immunol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1038\/nature13848","article-title":"CEACAM1 regulates TIM-3-mediated tolerance and exhaustion","volume":"517","author":"Huang","year":"2015","journal-title":"Nature"},{"key":"B129","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1038\/s42003-024-06762-w","article-title":"TIM-3 on myeloid cells promotes pulmonary inflammation through increased production of galectin-3","volume":"7","author":"Kim","year":"2024","journal-title":"Commun Biol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.618710","article-title":"One stone, two birds: The roles of Tim-3 in acute myeloid leukemia","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2022.103085","article-title":"Lymphocyte activation gene-3 (LAG-3) regulatory T cells: An evolving biomarker for treatment response in autoimmune diseases","volume":"21","author":"Gertel","year":"2022","journal-title":"Autoimmun Rev"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2020.102504","article-title":"LAG3 (CD223) and autoimmunity: Emerging evidence","volume":"112","author":"Hu","year":"2020","journal-title":"J Autoimmun"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-018-0217-9","article-title":"LAG-3 inhibits the activation of CD4(+) T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII","volume":"19","author":"Maruhashi","year":"2018","journal-title":"Nat Immunol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.11.010","article-title":"Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3","volume":"176","author":"Wang","year":"2019","journal-title":"Cell"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2022.03.013","article-title":"Binding of LAG-3 to stable peptide-MHC class II limits T cell function and suppresses autoimmunity and anti-cancer immunity","volume":"55","author":"Maruhashi","year":"2022","journal-title":"Immunity"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2025.06.004","article-title":"Proximity between LAG-3 and the T cell receptor guides suppression of T cell activation and autoimmunity","volume":"188","author":"Du","year":"2025","journal-title":"Cell"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2024.08.008","article-title":"Inhibitory co-receptor Lag3 supports Foxp3(+) regulatory T cell function by restraining Myc-dependent metabolic programming","volume":"57","author":"Kim","year":"2024","journal-title":"Immunity"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1100714","article-title":"Cutting edge: accelerated autoimmune diabetes in the absence of LAG-3","volume":"187","author":"Bettini","year":"2011","journal-title":"J Immunol"},{"key":"B139","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1084\/jem.20100466","article-title":"PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice","volume":"208","author":"Okazaki","year":"2011","journal-title":"J Exp Med"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.07.016","article-title":"LAG-3 and PD-1 synergize on CD8(+) T cells to drive T cell exhaustion and hinder autocrine IFN-gamma-dependent anti-tumor immunity","volume":"187","author":"Andrews","year":"2024","journal-title":"Cell"},{"key":"B141","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"key":"B142","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13075-017-1309-x","article-title":"Interleukin-10-producing LAG3+ regulatory T cells are associated with disease activity and abatacept treatment in rheumatoid arthritis","volume":"19","author":"Nakachi","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.05.021","article-title":"Proportion of CD4(+)CD49b(+)LAG-3(+) type 1 regulatory T cells in the blood of psoriasis patients inversely correlates with psoriasis area and severity index","volume":"138","author":"Kim","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B144","doi-asserted-by":"publisher","first-page":"594","DOI":"10.4049\/jimmunol.2100850","article-title":"Fewer LAG-3(+) T cells in relapsing-remitting multiple sclerosis and type 1 diabetes","volume":"208","author":"Jones","year":"2022","journal-title":"J Immunol"},{"key":"B145","doi-asserted-by":"publisher","first-page":"5748","DOI":"10.1038\/s41467-024-50007-7","article-title":"Start codon variant in LAG3 is associated with decreased LAG-3 expression and increased risk of autoimmune thyroid disease","volume":"15","author":"Saevarsdottir","year":"2024","journal-title":"Nat Commun"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2091","article-title":"Depletion of LAG-3(+) T cells translated to pharmacology and improvement in psoriasis disease activity: A phase I randomized study of mAb GSK2831781","volume":"109","author":"Ellis","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17557","article-title":"A randomised, double-blind, placebo-controlled study of the LAG-3-depleting monoclonal antibody GSK2831781 in patients with active ulcerative colitis","volume":"58","author":"D'Haens","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.956090","article-title":"The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application","volume":"13","author":"Huo","year":"2022","journal-title":"Front Immunol"},{"key":"B149","doi-asserted-by":"publisher","first-page":"e001014","DOI":"10.1136\/jitc-2020-001014","article-title":"LAG-3: from molecular functions to clinical applications","volume":"8","author":"Maruhashi","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B150","doi-asserted-by":"publisher","first-page":"2026.02.10.705171","DOI":"10.64898\/2026.02.10.705171","article-title":"Soluble LAG-3 identifies a dynamic early T cell activation window in self-reactivity, type 1 diabetes, and broader immune responses","author":"Roy","year":"2026","journal-title":"bioRxiv"},{"key":"B151","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/ni.1674","article-title":"The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells","volume":"10","author":"Yu","year":"2009","journal-title":"Nat Immunol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003081","article-title":"Cutting edge: TIGIT has T cell-intrinsic inhibitory functions","volume":"186","author":"Joller","year":"2011","journal-title":"J Immunol"},{"key":"B153","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41584-025-01296-9","article-title":"PD-1, BTLA and TIGIT as therapeutic targets for rheumatic disease","volume":"22","author":"Kuchroo","year":"2026","journal-title":"Nat Rev Rheumatol"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.02.012","article-title":"Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses","volume":"40","author":"Joller","year":"2014","journal-title":"Immunity"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1093\/jleuko\/qiae116","article-title":"TIGIT stimulation suppresses autoimmune uveitis by inhibiting Th17 cell infiltration","volume":"116","author":"Peters","year":"2024","journal-title":"J Leukoc Biol"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2015.12.002","article-title":"TIGIT overexpression diminishes the function of CD4 T cells and ameliorates the severity of rheumatoid arthritis in mouse models","volume":"340","author":"Zhao","year":"2016","journal-title":"Exp Cell Res"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12715","article-title":"TIGIT signalling pathway negatively regulates CD4(+) T-cell responses in systemic lupus erythematosus","volume":"151","author":"Mao","year":"2017","journal-title":"Immunology"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e27687","article-title":"Circulating TIGIT(+\/-)PD1(+)TPH, TIGIT (+\/-) PD1(+)TFH cells are elevated and their predicting role in systemic lupus erythematosus","volume":"10","author":"Luo","year":"2024","journal-title":"Heliyon"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1093\/immadv\/ltaa004","article-title":"DNAM1 and TIGIT balance the T cell response, with low T cell TIGIT expression corresponding to inflammation in psoriatic disease","volume":"1","author":"Jacobs","year":"2021","journal-title":"Immunother Adv"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.649135","article-title":"TIGIT-Fc as a potential therapeutic agent for fetomaternal tolerance","volume":"12","author":"Fu","year":"2021","journal-title":"Front Immunol"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1093\/jimmun\/vkaf283.499","article-title":"Building immune tolerance with a novel recombinant Adv5-TIGIT vector 2598","volume":"214","author":"Oh","year":"2025","journal-title":"J Immunol"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1370907","article-title":"TIGIT acts as an immune checkpoint upon inhibition of PD1 signaling in autoimmune diabetes","volume":"15","author":"Trivedi","year":"2024","journal-title":"Front Immunol"},{"key":"B163","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/s42003-023-04874-3","article-title":"Anti-human-TIGIT agonistic antibody ameliorates autoimmune diseases by inhibiting Tfh and Tph cells and enhancing Treg cells","volume":"6","author":"Kojima","year":"2023","journal-title":"Commun Biol"},{"key":"B164","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1007\/s00262-025-04128-7","article-title":"Anti-TIGIT therapies: a review of preclinical and clinical efficacy and mechanisms","volume":"74","author":"Sundstrom","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"B165","doi-asserted-by":"publisher","first-page":"eaay0524","DOI":"10.1126\/science.aay0524","article-title":"VISTA is a checkpoint regulator for na\u00efve T cell quiescence and peripheral tolerance","volume":"367","author":"ElTanbouly","year":"2020","journal-title":"Science"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.654960","article-title":"Roles of BTLA in immunity and immune disorders","volume":"12","author":"Ning","year":"2021","journal-title":"Front Immunol"},{"key":"B167","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.addr.2018.12.005","article-title":"Targeting the CD40-CD40L pathway in autoimmune diseases: Humoral immunity and beyond","volume":"141","author":"Karnell","year":"2019","journal-title":"Adv Drug Delivery Rev"},{"key":"B168","doi-asserted-by":"publisher","first-page":"3326","DOI":"10.3390\/cells11203326","article-title":"Synovial macrophages expression of OX40L is required for follicular helper T cells differentiation in the joint microenvironment","volume":"11","author":"Cai","year":"2022","journal-title":"Cells"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1002\/art.40479","article-title":"Brief report: A randomized, double-blind, parallel-group, placebo-controlled, multiple-dose study to evaluate AMG 557 in patients with systemic lupus erythematosus and active lupus arthritis","volume":"70","author":"Cheng","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1002\/art.20221","article-title":"Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate","volume":"50","author":"Genovese","year":"2004","journal-title":"Arthritis Rheum"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1002\/art.40580","article-title":"ABT-122, a bispecific dual variable domain immunoglobulin targeting tumor necrosis factor and interleukin-17A, in patients with rheumatoid arthritis with an inadequate response to methotrexate: A randomized, double-blind study","volume":"70","author":"Genovese","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"B172","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2147\/dddt.S16489","article-title":"Abatacept in the treatment of polyarticular JIA: development, clinical utility, and place in therapy","volume":"5","author":"Goldzweig","year":"2011","journal-title":"Drug Des Devel Ther"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000813","article-title":"Abatacept in combination with methotrexate in Japanese biologic-naive patients with active rheumatoid arthritis: a randomised placebo-controlled phase IV study","volume":"4","author":"Matsubara","year":"2018","journal-title":"RMD Open"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-017-1488-5","article-title":"Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting","volume":"20","author":"Alten","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4638-7","article-title":"A selective CD28 antagonist and rapamycin synergise to protect against spontaneous autoimmune diabetes in NOD mice","volume":"61","author":"Besan\u00e7on","year":"2018","journal-title":"Diabetologia"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1002\/art.38790","article-title":"Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study","volume":"66","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2007.01996.x","article-title":"Combined coinhibitory and costimulatory modulation with anti-BTLA and CTLA4Ig facilitates tolerance in murine islet allografts","volume":"7","author":"Truong","year":"2007","journal-title":"Am J Transplant"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1097\/01.Tp.0000085010.39567.Fb","article-title":"Stimulating PD-1-negative signals concurrent with blocking CD154 co-stimulation induces long-term islet allograft survival","volume":"76","author":"Gao","year":"2003","journal-title":"Transplantation"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1038\/381434a0","article-title":"Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways","volume":"381","author":"Larsen","year":"1996","journal-title":"Nature"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199712270-00035","article-title":"Prevention of chronic rejection in mouse aortic allografts by combined treatment with CTLA4-Ig and anti-CD40 ligand monoclonal antibody","volume":"64","author":"Sun","year":"1997","journal-title":"Transplantation"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0900339","article-title":"Anti-CD40 monoclonal antibody synergizes with CTLA4-Ig in promoting long-term graft survival in murine models of transplantation","volume":"183","author":"Gilson","year":"2009","journal-title":"J Immunol"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2012.04029.x","article-title":"CTLA4Ig prevents alloantibody formation following nonhuman primate islet transplantation using the CD40-specific antibody 3A8","volume":"12","author":"Badell","year":"2012","journal-title":"Am J Transplant"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.16.8789","article-title":"CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates","volume":"94","author":"Kirk","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"B184","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.3390\/life13081779","article-title":"Inflammatory bowel disease as a paradoxical reaction to anti-TNF-alpha treatment-a review","volume":"13","author":"Mihai","year":"2023","journal-title":"Life (Basel)"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1177\/20499361251368006","article-title":"Circulating TNF-alpha levels in rheumatoid arthritis: a systematic review and meta-analysis and comparison to TNF-alpha levels in sepsis","volume":"12","author":"Scherger","year":"2025","journal-title":"Ther Adv Infect Dis"},{"key":"B186","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.reuma.2012.05.001","article-title":"Abatacept use in rheumatoid arthritis: evidence review and recommendations","volume":"9","author":"Martin Mola","year":"2013","journal-title":"Reumatol Clin"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100726","article-title":"Combination therapy of abatacept and anakinra in children with refractory systemic juvenile idiopathic arthritis: a retrospective case series","volume":"38","author":"Record","year":"2011","journal-title":"J Rheumatol"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.115429","article-title":"Advancing insights into psoriasis: from pathogenesis to current and emerging therapies","volume":"165","author":"Goncalves","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-024-01035-3","article-title":"Chimeric antigen receptor T cell therapy for autoimmune disease","volume":"24","author":"Chung","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2022.103116","article-title":"The role of B cell metabolism in autoimmune diseases","volume":"21","author":"Mubariki","year":"2022","journal-title":"Autoimmun Rev"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N Engl J Med"},{"key":"B192","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/ncprheum0424","article-title":"Drug insight: the mechanism of action of rituximab in autoimmune disease--the immune complex decoy hypothesis","volume":"3","author":"Taylor","year":"2007","journal-title":"Nat Clin Pract Rheumatol"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"Lancet"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N Engl J Med"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)00023-5","article-title":"CD19-targeted CAR T cells in refractory antisynthetase syndrome","volume":"401","author":"M\u00fcller","year":"2023","journal-title":"Lancet"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2024.03.002","article-title":"CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis","volume":"5","author":"Fischbach","year":"2024","journal-title":"Med"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02964-1","article-title":"Bispecific T cell engager therapy for refractory rheumatoid arthritis","volume":"30","author":"Bucci","year":"2024","journal-title":"Nat Med"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2408786","article-title":"BCMA-targeted T-cell-engager therapy for autoimmune disease","volume":"391","author":"Hagen","year":"2024","journal-title":"N Engl J Med"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1097\/cm9.0000000000003111","article-title":"Dawn of CAR-T cell therapy in autoimmune diseases","volume":"137","author":"Liu","year":"2024","journal-title":"Chin Med J (Engl)"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1177\/0961203318783057","article-title":"Combination of rituximab and abatacept as an exit strategy for repetitive B-cell depletion in children with severe autoimmune diseases: a report of three cases","volume":"27","author":"Speth","year":"2018","journal-title":"Lupus"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.2337\/db20-1185","article-title":"Uncovering pathways to personalized therapies in type 1 diabetes","volume":"70","author":"Linsley","year":"2021","journal-title":"Diabetes"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1002\/art.41466","article-title":"Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis","volume":"73","author":"Atisha-Fregoso","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2025.102556","article-title":"Autoimmune-related adverse events induced by immune checkpoint inhibitors","volume":"94","author":"Sun","year":"2025","journal-title":"Curr Opin Immunol"},{"key":"B205","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/mdr2.70019","article-title":"The evolving landscape of immunotoxicity: Charting mechanisms and future strategies for immune checkpoint inhibitor adverse events","volume":"1","author":"Lin","year":"2025","journal-title":"Med Res"},{"key":"B206","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.3390\/cancers16142585","article-title":"Immune-related adverse events induced by immune checkpoint inhibitors and CAR-T cell therapy: A comprehensive imaging-based review","volume":"16","author":"Pozzessere","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104808","article-title":"T cell-mediated mechanisms of immune-related adverse events induced by immune checkpoint inhibitors","volume":"213","author":"Li","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1111\/imr.13247","article-title":"Immune-related adverse events after immune check point inhibitors: Understanding the intersection with autoimmunity","volume":"318","author":"Singh","year":"2023","journal-title":"Immunol Rev"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2025.103943","article-title":"Immune checkpoint inhibitor-induced inflammatory arthritis vs rheumatoid arthritis: A comparative review","volume":"25","author":"Georgios","year":"2026","journal-title":"Autoimmun Rev"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1584675","article-title":"Immune checkpoint inhibitor-induced thyroiditis and its potential mechanisms","volume":"16","author":"Mao","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B211","doi-asserted-by":"publisher","first-page":"S95","DOI":"10.1016\/j.cmi.2018.01.030","article-title":"Consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors)","volume":"24","author":"Redelman-Sidi","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1733357","article-title":"A composite score of serum cytokines enables early identification of patients at high risk for irAEs under immune checkpoint inhibition","volume":"16","author":"Flatt","year":"2025","journal-title":"Front Immunol"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2022.102266","article-title":"The increasing prevalence of autoimmunity and autoimmune diseases: an urgent call to action for improved understanding, diagnosis, treatment, and prevention","volume":"80","author":"Miller","year":"2023","journal-title":"Curr Opin Immunol"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-0343-4","article-title":"Immune checkpoint signaling and cancer immunotherapy","volume":"30","author":"He","year":"2020","journal-title":"Cell Res"},{"key":"B215","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/bjc.2017.136","article-title":"Hallmarks of response to immune checkpoint blockade","volume":"117","author":"Cogdill","year":"2017","journal-title":"Br J Cancer"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.11.015","article-title":"Spatial distribution and functional analysis define the action pathway of Tim-3\/Tim-3 ligands in tumor development","volume":"30","author":"Wang","year":"2022","journal-title":"Mol Ther"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.911919","article-title":"TIGIT as a promising therapeutic target in autoimmune diseases","volume":"13","author":"Yue","year":"2022","journal-title":"Front Immunol"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2020.12.008","article-title":"VISTA: A mediator of quiescence and a promising target in cancer immunotherapy","volume":"42","author":"Yuan","year":"2021","journal-title":"Trends Immunol"},{"key":"B219","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41392-024-01952-8","article-title":"Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders","volume":"9","author":"Song","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2021.08.008","article-title":"OX40L blockade cellular nanovesicles for autoimmune diseases therapy","volume":"337","author":"Fu","year":"2021","journal-title":"J Control Release"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.1111\/imm.70014","article-title":"The role and mechanism of anti-ICOS mAb in experimental autoimmune encephalomyelitis","volume":"176","author":"Xiao","year":"2025","journal-title":"Immunology"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1725372\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:17:58Z","timestamp":1789031878000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1725372\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":221,"alternative-id":["10.3389\/fimmu.2026.1725372"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1725372","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"article-number":"1725372"}}